Tech Transfer eNews Blog

FutuRx launches start-up based on CNS research from Tel Aviv U and Glasgow U


By Jesse Schwartz
Published: January 15th, 2020

FutuRx, Israel’s leading incubator for biopharmaceutical start-ups, has launched a new venture in collaboration with Ramot at Tel-Aviv University and Glasgow University to commercialize a new method for treating neurological disorders.

The new company, Epeius Pharma, is developing a novel biological vehicle for delivering therapeutic proteins into the central nervous system (CNS). Successful therapeutic delivery is highly challenging in CNS diseases because of the blood-brain barrier, which tightly regulates the transport of molecules to the brain and blocks most therapeutic agents. The technology from Epeius will utilize a unique biological platform based on the brain parasite Toxoplasma and apply cell and gene therapy approaches to overcome these challenges.

Researchers at Tel Aviv University and the University of Glasgow developed the technology, and  Ramot, the tech transfer arm of Tel Aviv University, licensed it to Epeius. With the support of FutuRx, the start-up will focus on developing its product with the goal of entering clinical trials and securing patent protection.

Lilach Sheiner and Oded Rechavi, the researchers behind Epeius, comment, “We are delighted to partner with FutuRx to launch Epeius Pharma, which will leverage the natural pathways of the brain parasite Toxoplasma gondii to deliver therapeutics into the brain.”

Source: Cision

Posted under: Tech Transfer e-News

Twitter Facebook Linkedin Pinterest Email

No Comments so far ↓

There are no comments yet...Kick things off by filling out the form below.

Leave a Comment